Cited by 357Sirtuins and Resveratrol in MedicineCancer, Lipids, and MetabolismCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 4 of the 34 sources its claims cite were checked for support.

Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP

Open access

Abstract

The sterol regulatory element-binding protein (SREBP) transcription factor family is a critical regulator of lipid and sterol homeostasis in eukaryotes. In mammals, SREBPs are highly active in the fed state to promote the expression of lipogenic and cholesterogenic genes and facilitate fat storage. During fasting, SREBP-dependent lipid/cholesterol synthesis is rapidly diminished in the mouse liver; however, the mechanism has remained incompletely understood. Moreover, the evolutionary conservation of fasting regulation of SREBP-dependent programs of gene expression and control of lipid homeostasis has been unclear. We demonstrate here a conserved role for orthologs of the NAD+-dependent deacetylase SIRT1 in metazoans in down-regulation of SREBP orthologs during fasting, resulting in inhibition of lipid synthesis and fat storage. Our data reveal that SIRT1 can directly deacetylate SREBP, and modulation of SIRT1 activity results in changes in SREBP ubiquitination, protein stability, and target gene expression. In addition, chemical activators of SIRT1 inhibit SREBP target gene expression in vitro and in vivo, correlating with decreased hepatic lipid and cholesterol levels and attenuated liver steatosis in diet-induced and genetically obese mice. We conclude that SIRT1 orthologs play a critical role in controlling SREBP-dependent gene regulation governing lipid/cholesterol homeostasis in metazoans in response to fasting cues. These findings may have important biomedical implications for the treatment of metabolic disorders associated with aberrant lipid/cholesterol homeostasis, including metabolic syndrome and atherosclerosis.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

SIRT1 orthologs are required for fasting-dependent down-regulation of SREBP and its lipogenic/cholesterogenic target genes across metazoans. SIRT1 directly deacetylates SREBP, promoting its ubiquitination and turnover, and SIRT1 activators reduce SREBP target expression and hepatosteatosis in obese mice.

Key findings

  • In *C. elegans*, fasting decreases intestinal lipids and triglycerides in wild-type animals, but not in *sir-2.1*-null animals; *sir-2.1* loss also prevents fasting-dependent down-regulation of SBP-1 target genes such as *fat-7* and *lbp-6*, while *sir-2.1* overexpression lowers fat storage and target gene expression.
  • In *Drosophila*, larvae homozygous for a *dSir2* deletion show increased transcription of dSREBP target genes encoding acetyl-CoA synthase, acetyl-CoA carboxylase, and fatty acid synthase, especially during fasting.
  • In mouse liver, SIRT1 shRNA knockdown reduces fasting-dependent down-regulation of FASN, ELOVL6, and SREBP-1c; SIRT1 liver-specific knockout livers show broad up-regulation of SREBP-1 and SREBP-2 targets, including lipogenic and cholesterol biosynthesis genes.
  • SIRT1 directly deacetylates SREBP-1a in an NAD+-dependent manner; nicotinamide increases SREBP-1a half-life from ~1 h to ~6 h, and SRT2183 increases SREBP-1a ubiquitination and decreases nuclear SREBP-1. In *ob/ob* mice on high-fat diet, SRT1720 (100 mg/kg daily for 2 or 4 wk) lowers hepatic FASN and SREBP-1c expression at 4 wk and improves hepatosteatosis.

Methods

  • Conserved invertebrate assays used *C. elegans* fasting, Sudan Black lipid staining, thin-layer/gas chromatography for triglycerides, qRT-PCR, *sbp-1* RNAi, and GFP reporters for *fat-7* and SBP-1; *Drosophila* Sir2-null third instar larvae were fasted for 24 h and analyzed by qRT-PCR.
  • Mammalian experiments used SIRT1 shRNA adenovirus in mouse liver, SIRT1 liver-specific knockout mice, SIRT1 knockout MEFs, human cell lines (HeLa, HEK293T, IMR-90), immunoprecipitation/immunoblotting, immunofluorescence, in vitro deacetylation assays with GST-SIRT1, cycloheximide stability assays, and microarray analysis of SIRT1 LKO livers.
  • In vivo SIRT1 activator studies used 6-wk-old *ob/ob* mice fed a high-fat diet, acclimated 2 wk, then dosed with SRT1720 (100 mg/kg) or vehicle by oral gavage daily for 2 or 4 wk (n = 5 per group), with liver lipid extraction and qRT-PCR.

Limitations

  • The paper does not include a dedicated limitations section. It notes that the precise mechanistic details of how SIRT1 activators function are still debated (citing Ledford 2008; Pacholec et al. 2010), and that sirtuins may affect multiple metabolic processes, so down-regulation of SREBP activity is described as “a significant contributor” rather than the sole cause of decreased stored lipids.
  • The text acknowledges that effects of SIRT1 manipulations could be indirect through CBP/p300, though it reports that immunopurified p300 from SRT2183-treated cells did not show decreased histone acetylation activity.
  • It states that it is presently unclear whether AMPK also regulates SREBP in lower metazoans, and that deacetylation may play a minor role in SREBP turnover in nonfasted situations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1101/gad.1901210

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

4 of 34 cited sources checked · 0 supported · 0 flagged · accuracy not yet measured

Show all 82 claims

  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 16
39 of 39
  • The paper relies on this without support.

    Changes in SREBP target gene expression reflect changes in SREBP transcriptional activity.

    “We also found that treatment of human cell lines with SRT2183 results in significantly decreased expression of SREBP target genes in a dose-dependent manner, consistent with our model (Fig. 7D; data not shown).”
  • The paper relies on this without support.

    Nuclear abundance of SREBP isoforms reflects their functional activity.

    “We found that nicotinamide, sirtinol, and siRNA-mediated ablation of SIRT1 all increased the nuclear abundance of SREBP-1a and SREBP-2 in primary human fibroblasts (IMR-90) and cancer cells (HeLa S) (Fig. 6A,B; Supplemental Figs. 7, 8).”
  • The paper relies on this without support.

    FASN is an SREBP target gene.

    “Genetically (ob/ob) obese mice fed a high-fat diet and treated with SRT1720 daily for 2 and 4 wk exhibit significantly lower expression of the SREBP target gene FASN in the liver at 4 wk as compared with vehicle-treated mice (Fig. 7E).”
  • The paper relies on this without support.

    Liver weight and hepatic lipid content are valid measures of hepatosteatosis.

    “Importantly, ob/ob mice treated with SRT1720 for 4 wk have significantly improved hepatosteatosis, as judged by decreased liver weight and hepatic lipids (Fig. 7F; data not shown).”
  • The paper relies on this without support.

    The ob/ob mouse high-fat diet model is relevant to human metabolic syndrome/hepatosteatosis.

    “Genetically (ob/ob) obese mice fed a high-fat diet and treated with SRT1720 daily for 2 and 4 wk exhibit significantly lower expression of the SREBP target gene FASN in the liver at 4 wk as compared with vehicle-treated mice (Fig. 7E).”
  • The paper relies on this without support.

    RNAi-mediated SIRT1 ablation is specific for SIRT1.

    “We found that nicotinamide, sirtinol, and siRNA-mediated ablation of SIRT1 all increased the nuclear abundance of SREBP-1a and SREBP-2 in primary human fibroblasts (IMR-90) and cancer cells (HeLa S) (Fig. 6A,B; Supplemental Figs. 7, 8).”
6 of 6

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Sirtinol treatment duration differs between methods and figure legend

    Minor

    The methods specify a 20-hour treatment with 0.1 mM sirtinol, whereas the Figure 4B legend describes a 5-hour treatment at the same concentration.

1 of 1

Citations

Cites

Flagged first, then by citations

Show all 74 references

Research works printed but not linked: 1

  1. 10.1042/0264-6021:3500389 · DOI

Cited by

Sorted by citations

Items 101–200 of 357

Metadata

Authors
Walker, A. K., Yang, F., Jiang, K., Ji, J.-Y., Watts, J. L., Purushotham, A., Boss, O., Hirsch, M. L., Ribich, S., Smith, J. J., Israelian, K., Westphal, C. H., Rodgers, J. T., Shioda, T., Elson, S. L., Mulligan, P., Najafi-Shoushtari, H., Black, J. C., Thakur, J. K., Kadyk, L. C., Whetstine, J. R., Mostoslavsky, R., Puigserver, P., Li, X., Dyson, N. J., Hart, A. C., & Näär, A. M.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
  • Washington State University (US)
  • National Institutes of Health (US)
  • Exelixis (United States) (US)
  • Brown University (US)
Venue
Genes & Development
Published
2010-07-01
Volume
24
Issue
13
Pages
1403-1417
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2127088568
Cited by
357
References
74
Citations by year
2026: 7 · 2025: 14 · 2024: 17 · 2023: 24 · 2022: 12 · 2021: 26 · 2020: 30 · 2019: 19 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 24 · 2014: 36 · 2013: 33 · 2012: 28
Type
posted content
Language
en
Open access
Locations
  • Genes & Development (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of General Medical Sciences (R01GM093072, R01GM053203, R01GM071449)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074114, R01DK088190, R01DK084352, R01DK07833)
  • National Center for Research Resources
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
SIRT1, SREBP, fasting, lipid homeostasis, cholesterol homeostasis, protein deacetylation, ubiquitination, protein stability, hepatic lipid synthesis, hepatic steatosis, fat deposition, evolutionary conservation, SIRT1 activators, metabolic syndrome, atherosclerosis
MeSH terms
Acetylation, Animals, Benzamides, Cell Line, Cholesterol, Fasting, HeLa Cells, Heterocyclic Compounds, 4 or More Rings, Humans, Lipids, Naphthols, Niacinamide, Down-Regulation, Caenorhabditis elegans, Sirtuins, Mice, Sterol Regulatory Element Binding Protein 1, Sterol Regulatory Element Binding Protein 2, Protein Stability, Sirtuin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review